This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) closed the most recent trading day at $14.63, moving -1.48% from the previous trading session.
TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, TG Therapeutics (TGTX) closed at $14.70, marking a -1.41% move from the previous day.
TG Therapeutics (TGTX) Stock Moves -0.6%: What You Should Know
by Zacks Equity Research
In the latest trading session, TG Therapeutics (TGTX) closed at $14.79, marking a -0.6% move from the previous day.
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Universal Health Services (UHS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 2.03% and 1.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) closed at $19.34 in the latest trading session, marking a +1.79% move from the prior day.
TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) closed the most recent trading day at $18.43, moving -0.27% from the previous trading session.
TG Therapeutics (TGTX) Stock Moves -0.89%: What You Should Know
by Zacks Equity Research
In the latest trading session, TG Therapeutics (TGTX) closed at $14.50, marking a -0.89% move from the previous day.
TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) closed at $13.20 in the latest trading session, marking a +0.61% move from the prior day.
TG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
TG Therapeutics (TGTX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Company News for Dec 30, 2022
by Zacks Equity Research
Companies in The News Are: IMGN, TGTX, TSLA, MSFT
TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug
by Zacks Equity Research
The FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch the drug in the first quarter of 2023. Stock up.
Can TG Therapeutics (TGTX) Climb 155% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for TG Therapeutics (TGTX) points to a 154.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
3 Medical Products Stocks Navigating Industry Challenges (Revised)
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.
Zacks Industry Outlook Highlights QuidelOrtho, Lantheus and TG Therapeutics
by Zacks Equity Research
QuidelOrtho, Lantheus and TG Therapeutics are part of Zacks Industry Outlook article.
3 Medical Products Stocks Navigating Industry Challenges
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.
TG Therapeutics (TGTX) Upgraded to Buy: Here's Why
by Zacks Equity Research
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does TG Therapeutics (TGTX) Have the Potential to Rally 151% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 151.2% in TG Therapeutics (TGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
TG Therapeutics (TGTX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 21.21% and 97.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 Earnings Beat Estimates
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 15.63% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 225% Upside in TG Therapeutics (TGTX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 225.4% upside potential for TG Therapeutics (TGTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can TG Therapeutics (TGTX) Climb 193% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for TG Therapeutics (TGTX) points to a 192.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
TG Therapeutics (TGTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 38.78% and 590.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
NanoString Technologies (NSTG) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -37.10% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?